The association between depression and efavirenz-based antiretroviral treatment in people living with human immune-deficiency virus: a systematic review
DOI:
https://doi.org/10.18203/2349-3933.ijam20233208Keywords:
HIV, Efavirenz, Depression, PLHIVAbstract
The neuropsychiatric disturbance such as depression in people living with (PLHIV) requires serious attention as this affects their health outcome. Efavirenz (EFV)-based treatment has been associated with neuropsychiatric adverse events, but its mechanism still unknown. The purpose of this systematic review is to dissect recent studies regarding EFV and depression, in the hope to discover reasonings behind this association. PRISMA flow chart was used to search for the related literatures in the last five years (2018-2023). Targeted population was PLHIV on EFV-based ART only and/or compared with non-EFV-based ART. Relevant keywords used to search were HIV, efavirenz and depression. Five eligible articles were selected which included a total of 3272 PLHIV. Overall, three studies agreed that EFV-based ART was related to depression, while the other two studies did not. It was shown that EFV-based ART did cause neuropsychiatric adverse effects in the first few weeks of treatment, but subsided after several months. However, longer-term research is needed to determine its long-term effects. Variation of results in different studies must be influenced by the possible genetic factors, baseline depression, different social and psychological circumstances throughout the treatment and different assessment tools for depression. Depression on EFV-based treatment in PLHIV may manifest in the initial few weeks of treatment, and additional research is still needed to determine its effects throughout longer treatment durations. Early diagnosis of depression in PLHIV is essential to decide the best choice of ARV for better outcome.
References
Chen MH, Su TP, Chen TJ, Cheng JY, Wei HT, Bai YM. Identification of psychiatric disorders among human immunodeficiency virus-infected individuals in Taiwan, a nine-year nationwide population-based study. AIDS Care. 2012;24:1543-9.
Pao M, Lyon M, D’Angelo LJ, Schuman WB, Tipnis T, Mrazek DA. Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. Arch Pediatr Adolesc Med. 2000;154:240-4.
Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS. 2009;23:1859-65.
Kacanek D, Jacobson D, Spiegelman D, Wanke C, Issac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: A longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr. 2010;53:266-72.
Xiao J, Liu Y, Li B, Zhang L, Han J, Zhao H. Anxiety, depression, and sleep disturbances among people on long-term efavirenz-based treatment for HIV: a cross-sectional study in Beijing, China. BMC Psychiatry. 2022;22(1):710.
Serrão R, Piñero C, Velez J, Coutinho D, Maltez F, Lino S, et al. Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study. Int J Infect Dis. 2019;79:94-100.
Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. J Acquir Immune Def Syndr. 2015;69(4):422-9.
Dalwadi DA, Ozuna L, Harvey BH, Viljoen M, Schetz JA. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and other HIV-1 antiretroviral drugs. Pharmocol Rev. 2018;70:684-711.
Journot V, Chene G, De Castro N, Rancinan C, Cassuto J, Allard C, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: A substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42:1790-9.
Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161:1-10.
Chang JL, Tsai AC, Musinguzi N, Haberer JE, Boum Y, Muzoora C, et al. Depression and suicidal ideation among HIV-infected adults receiving efavirenz versus nevirapine in Uganda: A prospective cohort study. Ann Int Med. 2018;169(3):146-55.
Yijia LI, Zheng WA, Cheng Y, Becker JT, Martin E, Levine A, et al. Neuropsychological changes in efavirenz switch regimens. AIDS (London, England). 2019;33(8):1307.
Checa A, Castillo A, Camacho M, Tapia W, Hernandez I, Teran E. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador. AIDS Res Therapy. 2020;17:1-5.
Ophinni Y, Siste K, Wiwie M, Anindyajati G, Hanafi E, Damayanti R, et al. Suicidal ideation, psychopathology and associated factors among HIV-infected adults in Indonesia. BMC Psychiatry. 2020;20(1):1-10.
Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15(1):1-5.
Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother. 2014;69(2):491-9.
Huang R, Chen Z, Dolan S, Schetz JA, Dillon GH. The dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites. Neuropharmacology. 2017;121:167-78.
Amiya RM, Poudel KC, Poudel-Tandukar K, Pandey BD, Jimba M. Perceived family support, depression, and suicidal ideation among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley, Nepal. PLoS One. 2014;9:e90959.
Balthazar M, Diallo I, Pak VM. Metabolomics of sleep disorders in HIV: a narrative review. Sleep Breath. 2020;24(4):1333-7.
Cai S, Liu L, Wu X, Pan Y, Yu T, Ou H. Depression, Anxiety, Psychological Symptoms and Health-Related Quality of Life in People Living with HIV. Patient Prefer Adherence. 2020;14:1533-40.
Payne B, Chadwick TJ, Blamire A, Anderson KN, Parikh J, Qian J, et al. Does efavirenz replacement improve neurological function in treated HIV infection? HIV Med. 2017;18(9):690-5.
Wardhana A. Making better HIV treatments a reality in Indonesia. Medicines Patent Pool. 2020. Available at: https://medicinespatentpool.org/story-post/ making-better-hiv-treatments-a-reality-in-indonesia. Accessed on 12 August 2023.
